Inhibition of excessive scleroderma fibroblast collagen production by recombinant γ‐interferon: Association with a coordinate decrease in types I and III procollagen messenger RNA levels
The DOI matches its Crossref record, with a small difference in title or year; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The effects of recombinant γ‐interferon (rec γ‐IFN) on collagen production by confluent monolayer cultures of progressive systemic sclerosis (PSS) dermal fibroblasts were studied. Five cell lines obtained from patients with rapidly progressive disease of recent onset were examined. All PSS fibroblast cell lines exhibited increased collagen production when compared with normal skin cell lines. It was found that rec γ‐IFN caused potent inhibition of PSS fibroblast collagen production in a concentration‐dependent manner. Greater than 50% inhibition was observed with as little as 50 antiviral units/ml, and maximal effects were attained at a concentration of 500 units/ml. The rec γ‐IFN caused reproducible inhibition of collagen production by the 5 PSS fibroblast cell lines, ranging from 58.9% to 85.6% of control values. Measurement of type I and type III procollagen messenger RNA (mRNA) levels with specific complementary DNA probes demonstrated a coordinate reduction of >60% in mRNA for both transcripts in rec γ‐IFN‐treated cells, compared with control cells. These findings indicate that rec γ‐IFN can modulate the excessive collagen biosynthesis characteristic of PSS fibroblasts and that this effect can be explained largely by the γ‐IFN‐mediated decrease in specific collagen mRNAs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, interferon γ (IFNγ) inhibits collagen synthesis, sensitizes dermal fibroblast to Fas-mediated apoptosis (125, 126) and inhibits IL-4 effects (125).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [126]
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Kafatos, F. C., Jones, C. W., & Efstratiadis, A. (1979) · Nucleic Acids Research · doi:10.1093/nar/7.6.1541 · Cited by 1,360
Modified procedure for the assay of H3- or C14-labeled hydroxyproline
Juva, K., & Prockop, D. J. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90249-1 · Cited by 702
Chu, M.-L., Myers, J. C., Bernard, M. P., Ding, J.-F., & Ramirez, F. (1982) · Nucleic Acids Research · doi:10.1093/nar/10.19.5925 · Cited by 492
Convenient assay for interferons
Rubinstein, S., Familletti, P. C., & Pestka, S. (1981) · Journal of Virology · doi:10.1128/jvi.37.2.755-758.1981 · Cited by 481
Selective inhibition of human diploid fibroblast collagen synthesis by interferons.
Jimenez, S. A., Freundlich, B., & Rosenbloom, J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111480 · Cited by 329
Self-citationDuncan, M. R., & Berman, B. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.2.516 · Cited by 272
Cloning a cDNA for the pro-alpha 2 chain of human type I collagen.
Myers, J. C., Chu, M. L., Faro, S. H., Clark, W. J., Prockop, D. J., & Ramirez, F. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3516 · Cited by 190
Arey, L. B. (1936) · Physiological Reviews · doi:10.1152/physrev.1936.16.3.327 · Cited by 165
Inhibition of collagen synthesis by mononuclear cell supernates.
Jiménez, S. A., McArthur, W. P., & Rosenbloom, J. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.6.1421 · Cited by 141
Self-citation
Research works printed but not linked: 3
- Leroy EC, 1985, Scleroderma (systemic sclerosis), Textbook of Rheumatology, 1183
- Brouty‐Boye D, 1980, Inhibitory effects of interferons on cell multiplication, Lymphokine Res, 1, 99
- Maniatis T, 1982, Molecular Cloning, 196
Cited by
Dinarello, C. A., & Mier, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171506 · Cited by 463
Pathogenesis of Systemic Sclerosis
Pattanaik, D., Brown, M., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 405
Haverty, T. P., Kelly, C. J., Hines, W. H., Amenta, P. S., Watanabe, M., Harper, R. A., Kefalides, N. A., & Neilson, E. G. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.4.1359 · Cited by 306
Rook, A. H., Freundlich, B., Jegasothy, B. V., Perez, M. I., Barr, W. G., Jimenez, S. A., Rietschel, R. L., Wintroub, B., Kahaleh, M. B., & Varga, J. (1992) · Archives of Dermatology · doi:10.1001/archderm.1992.01680130051005 · Cited by 299
Self-citationNovel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
Jimenez, S. A., Hitraya, E., & Varga, J. (1996) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70294-5 · Cited by 181
Interferon alfa and gamma inhibit proliferation and collagen synthesis of human ito cells in culture
Mallat, A., Preaux, A.-M., Blazejewski, S., Rosenbaum, J., Dhumeaux, D., & Mavier, P. (1995) · Hepatology · doi:10.1002/hep.1840210418 · Cited by 180
Berman, B., & Duncan, M. R. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)70239-5 · Cited by 176
The Role of the Immune System in Conjunctival Wound Healing After Glaucoma Surgery
Chang, L., Crowston, J. G., Cordeiro, M. F., Akbar, A. N., & Khaw, P. T. (2000) · Survey of Ophthalmology · doi:10.1016/s0039-6257(00)00135-1 · Cited by 168
Granstein, R. D. (1990) · Archives of Dermatology · doi:10.1001/archderm.1990.01670340047006 · Cited by 166
Regulation of Collagen Gene Expression
Bornstein, P., & Sage, H. (1989) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60695-9 · Cited by 166
Fibrosis and immune dysregulation in systemic sclerosis
Chizzolini, C., Brembilla, N. C., Montanari, E., & Truchetet, M. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.016 · Cited by 165
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
“For example, interferon γ (IFNγ) inhibits collagen synthesis, sensitizes dermal fibroblast to Fas-mediated apoptosis (125, 126) and inhibits IL-4 effects (125).”
Interstitial lung disease in systemic sclerosis
Bussone, G., & Mouthon, L. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.012 · Cited by 150
Smooth muscle differentiation in scleroderma fibroblastic cells.
Sappino, A. P., Masouyé, I., Saurat, J. ‐., & Gabbiani, G. (1990) · Europe PMC (PubMed Central) · Cited by 125
Chizzolini, C., Parel, Y., De Luca, C., Tyndall, A., Åkesson, Scheja, A., & Dayer, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11129 · Cited by 110
Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial
Grassegger, Schuler, �., Hessenberger, Walder-Hantich, Jabkowski, Macheiner, Salmhofer, Zahel, Pinter, Herold, et al. (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02460.x · Cited by 123
Interleukin-1 increases collagen production and mRNA levels in cultured skin fibroblasts
Kähäri, V., Heino, J., & VUORIO, E. I. (1987) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(87)90169-8 · Cited by 118
Interferons and Collagen Production
Granstein, R. D., Flotte, T. J., & Amento, E. P. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12874789 · Cited by 116
Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts
Agarwal, S. K., Wu, M., Livingston, C. K., Parks, D. H., Mayes, M. D., Arnett, F. C., & Tan, F. K. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3221 · Cited by 113
Recombinant interferon-γ in the treatment of systemic sclerosis
Kahan, A., Amor, B., Menkes, C. J., & Strauch, G. (1989) · The American Journal of Medicine · doi:10.1016/s0002-9343(89)80150-0 · Cited by 104
Varga, J., Olsen, A. S., HERHAL, J., Constantine, G. M., Rosenbloom, J., & Jiménez, S. A. (1990) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1990.tb01890.x · Cited by 103
Self-citationHypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts
Hong, K.-H., Yoo, S.-A., Kang, S.-S., Choi, J.-J., Kim, W.-U., & Cho, C.-S. (2006) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2006.03199.x · Cited by 100
Structure, Biosynthesis and Gene Regulation of Collagens in Cartilage and Bone
von der Mark, K. (2006) · Elsevier eBooks · doi:10.1016/b978-012088562-6/50002-9 · Cited by 97
The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
Yamamoto, T. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-005-0635-z · Cited by 95
Duncan, M. R., & Berman, B. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112956 · Cited by 95
The ‘Connective Tissue Diseases’
Goodfield, M. J. D., Jones, S., & Veale, D. J. (2010) · Wiley eBooks · doi:10.1002/9781444317633.ch51 · Cited by 92
Duncan, M. R., & Berman, B. (1989) · Archives of Dermatological Research · doi:10.1007/bf00424266 · Cited by 92
Treatment of systemic sclerosis with γ-interferon
Hein, R., Behr, J., Hündgen, M., Hunzelmann, N., Meurer, M., Braun‐Falco, O., Urbanski, A., & Krieg, T. M. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb11824.x · Cited by 79
Ineffective Treatment of Keloids with Interferon Alpha-2b
Davison, S. P., Mess, S. A., Kauffman, L. C., & Alattar, A. A. (2006) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000195079.03742.cf · Cited by 77
Treatment of systemic sclerosis with recombinant interferon‐γ. A phase I/II clinical trial
Freundlich, B., Jiménez, S. A., Steen, V. D., Medsger, T. A., Szkolnicki, M., & Jaffe, H. S. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780351005 · Cited by 76
Self-citationCytokine production and serum levels in systemic sclerosis
Kantor, T. V., Friberg, D., Medsger, T. A., Buckingham, R. B., & Whiteside, T. L. (1992) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(92)90158-k · Cited by 74
Unemori, E., Bauer, E. A., & Amento, E. P. (1992) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12616665 · Cited by 72
Giacomelli, R., Cipriani, P., LATTANZIO, R., Franco, M. D., Locanto, M., Parzanese, I., Passacantando, A., Ciocci, A., & TONIETTI, G. (1997) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1997.d01-991.x · Cited by 69
Donohoe, J. F. (1992) · Kidney International · doi:10.1038/ki.1992.65 · Cited by 68
Kähäri, V., Heino, J., Vuorio, T. K., & VUORIO, E. I. (1988) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(88)90042-0 · Cited by 68
Ferrarini, M., Steene, V. V. D., Medsger, T. A., & Whiteside, T. L. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb08094.x · Cited by 64
Interferon-gamma in 5 patients with cutaneous radiation syndrome after radiation therapy
Gottlöber, P., Steinert, M., Bähren, W., Weber, L., Gerngroß, H., & Peter, R. U. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01542-x · Cited by 61
Shridharani, S. M., Magarakis, M., Manson, P. N., Singh, N., Basdag, B., & Rosson, G. D. (2010) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181afaab0 · Cited by 61
Krötzsch, E., Furuzawa‐Carballeda, J., de León, L. D., Reyes-Márquez, R., & Quiróz-Hernández, E. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00329.x · Cited by 60
Shen, H., Zhang, M., Minuk, G. Y., & Gong, Y. (2002) · BMC Cell Biology · doi:10.1186/1471-2121-3-9 · Cited by 60
Update on pathophysiology of scleroderma with special reference to immunoinflammatory events
Chizzolini, C. (2006) · Annals of Medicine · doi:10.1080/07853890601098152 · Cited by 58
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
Sharada, B., Kumar, A., Kakker, R., Adya, C. M., Pande, I., Uppal, S., Pande, J. N., Sunderam, K. R., & MALAVIYA, A. N. (1994) · Rheumatology International · doi:10.1007/bf00300808 · Cited by 58
Peter, R. U., Gottlöber, P., Nadeshina, N., Krähn, G. M., Braun‐Falco, O., & Plewig, G. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00116-9 · Cited by 57
Rook, A., Freundlich, B., Nahass, G. T., Washko, R. M., Macelis, B. J., Skolnicki, M., Bromley, P. A., Witmer, W. K., & Bv, J. (1989) · PubMed Central · Cited by 55
Self-citationActivation of Dermal Connective Tissue in Scleroderma
Kähäri, V. (1993) · Annals of Medicine · doi:10.1080/07853890.1993.12088576 · Cited by 55
Treatment of systemic sclerosis.
Medsger, T. A. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.suppl_4.877 · Cited by 54
The role of the acquired immune response in systemic sclerosis
Chizzolini, C., & Boin, F. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0509-1 · Cited by 52
Heckmann, M., Aumailley, M., Hatamochi, A., Chu, M., Timpl, R., & Krieg, T. (1989) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1989.tb14884.x · Cited by 51
Giacomelli, R., Cipriani, P., Fulminis, A., Barattelli, G., Matucci‐Cerinic, M., D’Alò, S., Cifone, M. G., & TONIETTI, G. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01603.x · Cited by 48
Interferon Treatments: How to Use an Endogenous System as a Therapeutic Agent
DIANZANI, F. (1992) · Journal of Interferon Research · doi:10.1089/jir.1992.1992.109 · Cited by 47
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy
Thannickal, V. J., Flaherty, K. R., Martínez, F. J., & Lynch, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.8.1671 · Cited by 45
Higashi, K., Kouba, D. J., Song, Y., Uitto, J., & Mauviel, A. (1998) · Matrix Biology · doi:10.1016/s0945-053x(98)90016-6 · Cited by 43
Allanore, Y., Borderie, D., Hilliquin, P., Hernvann, A., Levacher, M., Lemaréchal, H., Ekindjian, O. G., & Kahan, A. (2001) · Rheumatology · doi:10.1093/rheumatology/40.10.1089 · Cited by 42
Needleman, B. W., Ordóñez, J. V., Taramelli, D., Alms, W. J., Gayer, K., & Choi, J. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330611 · Cited by 39
Yamamoto, T. (2002) · Clinical Immunology · doi:10.1006/clim.2001.5169 · Cited by 38
Enhanced wound healing in animal models by interferon and an interferon inducer
Bhartiya, D., Sklarsh, J. W., & Maheshwari, R. K. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041500214 · Cited by 36
Systemic Sclerosis after Interferon Alphacon-1 Therapy for Hepatitis C
Tahara, H., Kojima, A., Hirokawa, T., Oyama, T., Naganuma, A., Maruta, S., Okada, K., Ban, S., Yoshida, K., Takagi, H., et al. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6328 · Cited by 35
Treatment of Systemic Sclerosis
Steen, V. D. (2001) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200102050-00006 · Cited by 34
Molteni, M., Bella, S. D., Mascagni, B., Bazzi, S., Zulian, C., Compasso, S., LESSI, M., & Scorza, R. (1999) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1999.00842.x · Cited by 32
Interferon-γ1bfor the treatment of idiopathic pulmonary fibrosis
Bouros, D. E., Antoniou, K. M., Τzouvelekis, Α., & Siafakas, N. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1051 · Cited by 30
Effect of IL-12 Encoding Plasmid Administration on Tight-Skin Mouse
Tsuji-Yamada, J., Nakazawa, M., Takahashi, K., Iijima, K., Hattori, S., Okuda, K., Minami, M., Ikezawa, Z., & Sasaki, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4171 · Cited by 30
Pneumopathie infiltrante diffuse de la sclérodermie systémique
Mouthon, L., BEREZNE, A., Brauner, M., Kambouchner, M., Guillevin, L., & Valeyre, D. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)92767-9 · Cited by 26
Varga, J. (1997) · Archives of Dermatology · doi:10.1001/archderm.1997.03890410093013 · Cited by 26
Effect of interferon-γ on experimental scleroderma induced by bleomycin
Yamamoto, T., Takagawa, S., Kuroda, M., & Nishioka, K. (2000) · Archives of Dermatological Research · doi:10.1007/s004030000136 · Cited by 25
Nguyen, K. D., Hoang, A. T., & Lee, D. A. (1994) · PubMed · Cited by 24
DERMAL CONNECTIVE TISSUE MODULATED BY PHARMACOLOGIC AGENTS
Oikarinen, A. (1992) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1992.tb03916.x · Cited by 23
Takeda, K., Hatamochi, A., Arakawa, M., & Ueki, H. (1993) · Archives of Dermatological Research · doi:10.1007/bf00373353 · Cited by 22
Lymphocyte modulation of fibroblast function in systemic sclerosis
Piela, T. H., & Korn, J. H. (1994) · Clinics in Dermatology · doi:10.1016/0738-081x(94)90289-5 · Cited by 22
Emerging drugs for idiopathic pulmonary fibrosis
Thannickal, V. J., Flaherty, K. R., Hyzy, R. C., & Lynch, J. P. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.707 · Cited by 21
RE: INTERNATIONAL CONFERENCE ON PEYRONIE'S DISEASE: ADVANCES IN BASIC AND CLINICAL RESEARCH
Gomahr, A., Kunit, G., Jungwirth, A., Mack, D., & Frick, J. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)68222-3 · Cited by 20
Strange, A. P., Aguayo, S. D., Ahmed, T., Mordan, N. J., Stratton, R. J., Porter, S. R., Parekh, S., & Bozec, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s118690 · Cited by 19
Padula, S. J., Broketa, G., Sampieri, A., Arakawa, M., Matucci‐Cerinic, M., Downie, E., & Korn, J. H. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370918 · Cited by 19
Dai, B., Ding, L., Zhao, L., Zhu, H., & Luo, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826839 · Cited by 17
Expression of HLA class II antigens on skin fibroblasts in scleroderma
Branchet, M., Boisnic, S., Blétry, O., Robert, L., Charron, D. J., & Francès, C. (1992) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1992.tb11814.x · Cited by 15
Dermatologic Uses of Interferons
Berman, B., & Sequeira, M. J. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30076-7 · Cited by 15
Adhesion Molecules in Scleroderma: Collagen Binding Integrins
Kupper, T. S. (1995) · International Reviews of Immunology · doi:10.3109/08830189509056714 · Cited by 14
Advances in the treatment of idiopathic pulmonary fibrosis
Sergew, A., & Brown, K. M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1102886 · Cited by 12
BERMAN, B., & Wietzerbin, J. (1992) · Journal of Dermatological Science · doi:10.1016/0923-1811(92)90040-i · Cited by 11
Wang, J. C. C., Lang, H., Liao, P., & Wong, A. (1992) · American Journal of Hematology · doi:10.1002/ajh.2830400202 · Cited by 11
Treatment of Systemic Sclerosis
Medsger, T. A. (1989) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)01006-1 · Cited by 11
Tsao, M., Ferrarini, M., Evans, C. H., Ambro, A., & Whiteside, T. L. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90227-4 · Cited by 11
Boin, F., & Chizzolini, C. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_13 · Cited by 10
The ‘Connective Tissue Diseases’
Goodfield, M. J. D., Jones, S. K., & Veale, D. J. (2004) · Wiley eBooks · doi:10.1002/9780470750520.ch56 · Cited by 8
SHENG, F. Y., Ohta, A., & Yamaguchi, M. (1994) · Internal Medicine · doi:10.2169/internalmedicine.33.466 · Cited by 7
Bryckaert, M., Fontenay, M., Lioté, F., Bellucci, S., Cariou, R., & Tobelem, G. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.11.776 · Cited by 7
Norris, D. A., Huff, J. C., & Weston, W. L. (1989) · Journal of Investigative Dermatology · doi:10.1038/jid.1989.62 · Cited by 5
Boin, F., & Chizzolini, C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-5774-0_15 · Cited by 2
0030 Spatial orchestration of skin fibrosis by a CD8 T cell-ADAM12+ myofibroblast axis
Boothby, I. C., Gan, C., Johri, V., Flynn, E., Kazmi, M., Maliskova, L., Shaikh, S., Combes, A., Fragiadakis, G. K., Neuhaus, I., et al. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.06.061 · Cited by 1
Joel Rosenbloom and the revolution in biomedical research
Rosenbloom, J. (2022) · Connective Tissue Research · doi:10.1080/03008207.2022.2047668 · Cited by 1
Self-citationT cells in the pathogenesis of systemic sclerosis
Sakkas, L. I., & Simopoulou, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85831-1.00022-x · Cited by 1
Les interférons ont-ils une action antifibrosante ?Le point de vue de l'interniste
Blétry, O., & Somogyi, A. (2002) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(02)00667-7 · Cited by 1
Lymphocytes in the liver and hepatic iron toxicity : human and animal models of iron overload
Cardoso, E. M. (2000) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/jbjx-7a42 · Cited by 1
Cohen, J. J., Harrington, J. T., & Zusman, C. J. (1992)
Drugs Acting on Dermal Connective Tissue
Nusgens, B., & Lapière, C. M. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-74054-1_27
Sasaki, T. (1990) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.52.219
Chang, L. (2002) · OpenGrey (Institut de l'Information Scientifique et Technique)
Adaptive Immunity in Interstitial Lung Disease
Winkler, J., & Herzog, E. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00018-4
Metadata
- Authors
- Rosenbloom, J., Feldman, G., Freundlich, B., & Jimenez, S. A.
- Affiliations
- University of Pennsylvania (US)
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1986-07
- Volume
- 29
- Issue
- 7
- Pages
- 851-856
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2034254900
- Cited by
- 101
- References
- 16
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 3
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arthritis & Rheumatism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (2r01am019616-08)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- interferon-gamma, systemic sclerosis, dermal fibroblasts, collagen synthesis, type I procollagen, type III procollagen, procollagen mRNA, antifibrotic therapy
- MeSH terms
- Adult, Cell Line, Collagen, Dose-Response Relationship, Drug, Female, Fibroblasts, Humans, Interferon-gamma, Male, Middle Aged, Nucleic Acid Hybridization, Procollagen, Recombinant Proteins, RNA, Messenger, Scleroderma, Systemic, Skin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.